AB-SCIEX
The market for life-saving targeted biologic therapies is growing rapidly. With this growth comes demand for new workflow solutions. Solutions are needed to allow scientists to predict more accurately the efficacy of new biopharmaceuticals, reduce their time to market and detect potential issues before they lead to costly product recalls.
AB SCIEX recently launched one such solution, the CESI-MS, a capillary electrophoresis separation-electrospray ionisation system for ultra-low flow separations coupled with mass spectrometry. According to AB SCIEX, CESI-MS represents the industry’s first commercially available ESI module for biologics. It can be integrated with the AB Sciex TripleTOF 5600+ mass spectrometry system for accurate, high-resolution mass measurements, ideal for advancing biopharmaceutical discovery and development.
The CESI-8000 technology is a single approach, which uses less sample volume from a single digest, has increased sensitivity and resolution through ultra-low flow separations, has a shorter run time and can be used to gain accurate information about post-translational modifications of proteins, says AB SCIEX.
The technology is said to put power into the hands of biopharma scientists for the highly accurate quantitative analysis of large molecules, ultimately helping to save more lives and address the unmet needs of scientists in biopharma.
AB SCIEX, www.absciex.com.